GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (BUE:GILD) » Definitions » Cyclically Adjusted PB Ratio

Gilead Sciences (BUE:GILD) Cyclically Adjusted PB Ratio : 4.16 (As of Jun. 05, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Gilead Sciences Cyclically Adjusted PB Ratio?

As of today (2024-06-05), Gilead Sciences's current share price is ARS20203.50. Gilead Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was ARS4,860.09. Gilead Sciences's Cyclically Adjusted PB Ratio for today is 4.16.

The historical rank and industry rank for Gilead Sciences's Cyclically Adjusted PB Ratio or its related term are showing as below:

BUE:GILD' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 3.56   Med: 7.31   Max: 28.67
Current: 3.56

During the past years, Gilead Sciences's highest Cyclically Adjusted PB Ratio was 28.67. The lowest was 3.56. And the median was 7.31.

BUE:GILD's Cyclically Adjusted PB Ratio is ranked worse than
72.19% of 730 companies
in the Drug Manufacturers industry
Industry Median: 1.885 vs BUE:GILD: 3.56

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Gilead Sciences's adjusted book value per share data for the three months ended in Mar. 2024 was ARS11,850.011. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ARS4,860.09 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Gilead Sciences Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Gilead Sciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Cyclically Adjusted PB Ratio Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.83 4.71 5.04 5.27 4.59

Gilead Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.95 4.50 4.28 4.59 4.06

Competitive Comparison of Gilead Sciences's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, Gilead Sciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Cyclically Adjusted PB Ratio falls into.



Gilead Sciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Gilead Sciences's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=20203.50/4860.09
=4.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Gilead Sciences's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=11850.011/131.7762*131.7762
=11,850.011

Current CPI (Mar. 2024) = 131.7762.

Gilead Sciences Quarterly Data

Book Value per Share CPI Adj_Book
201406 85.670 100.560 112.265
201409 75.459 100.428 99.013
201412 87.997 99.070 117.048
201503 102.588 99.621 135.701
201506 100.470 100.684 131.496
201509 112.996 100.392 148.321
201512 168.696 99.792 222.764
201603 145.152 100.470 190.380
201606 163.177 101.688 211.459
201609 190.330 101.861 246.227
201612 228.554 101.863 295.672
201703 241.116 102.862 308.892
201706 286.293 103.349 365.040
201709 333.107 104.136 421.523
201712 298.425 104.011 378.088
201803 319.145 105.290 399.429
201806 417.052 106.317 516.922
201809 650.125 106.507 804.372
201812 629.015 105.998 781.989
201903 673.520 107.251 827.538
201906 797.862 108.070 972.885
201909 910.189 108.329 1,107.190
201912 1,063.507 108.420 1,292.610
202003 1,092.251 108.902 1,321.678
202006 984.153 108.767 1,192.343
202009 1,033.613 109.815 1,240.320
202012 1,181.243 109.897 1,416.417
202103 1,361.400 111.754 1,605.307
202106 1,488.409 114.631 1,711.022
202109 1,672.778 115.734 1,904.641
202112 1,696.777 117.630 1,900.840
202203 1,704.863 121.301 1,852.090
202206 1,941.785 125.017 2,046.773
202209 2,335.889 125.227 2,458.063
202212 2,855.562 125.222 3,005.029
202303 3,323.684 127.348 3,439.262
202306 4,071.917 128.729 4,168.315
202309 6,261.776 129.860 6,354.199
202312 6,615.127 129.419 6,735.592
202403 11,850.011 131.776 11,850.011

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Gilead Sciences  (BUE:GILD) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Gilead Sciences Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences (BUE:GILD) Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.